ATE495255T1 - Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs - Google Patents

Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs

Info

Publication number
ATE495255T1
ATE495255T1 AT99942154T AT99942154T ATE495255T1 AT E495255 T1 ATE495255 T1 AT E495255T1 AT 99942154 T AT99942154 T AT 99942154T AT 99942154 T AT99942154 T AT 99942154T AT E495255 T1 ATE495255 T1 AT E495255T1
Authority
AT
Austria
Prior art keywords
scary
phenotype
gene
mouse
leads
Prior art date
Application number
AT99942154T
Other languages
English (en)
Inventor
Mary Brunkow
Eric Jeffery
Kathryn Hjerrild
Fred Ramsdell
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE495255T1 publication Critical patent/ATE495255T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99942154T 1998-08-11 1999-08-11 Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs ATE495255T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9619598P 1998-08-11 1998-08-11
PCT/US1999/018407 WO2000009693A2 (en) 1998-08-11 1999-08-11 Identification of the gene causing the mouse scurfy phenotype and its human ortholog

Publications (1)

Publication Number Publication Date
ATE495255T1 true ATE495255T1 (de) 2011-01-15

Family

ID=22256264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942154T ATE495255T1 (de) 1998-08-11 1999-08-11 Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs

Country Status (8)

Country Link
US (9) US6414129B1 (de)
EP (1) EP1105479B1 (de)
JP (4) JP4351807B2 (de)
AT (1) ATE495255T1 (de)
AU (1) AU5559499A (de)
CA (1) CA2339409A1 (de)
DE (1) DE69943129D1 (de)
WO (1) WO2000009693A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019026A1 (en) * 1995-06-05 2002-02-14 Daniel R. Soppet Human g-protein receptor hgber32
EP1105479B1 (de) * 1998-08-11 2011-01-12 Darwin Discovery Limited Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
AU2001285467A1 (en) * 2000-08-21 2002-03-04 Celltech R And D, Inc. Methods for detecting mutations in the human scurfy/foxp3 gene
EP1967525B1 (de) * 2001-05-08 2012-11-14 Darwin Molecular Corporation Verfahren zur Regulierung der Immunfunktion in Primaten unter Verwendung des foxp3-Proteins
EP2064350B1 (de) * 2006-11-27 2013-01-02 Ludwig Institute for Cancer Research Ltd. Expression von foxp3 durch krebszellen
US20100310635A1 (en) * 2007-04-25 2010-12-09 Engin Ozkaynak Compositions and Methods for Regulating T-Cell Activity
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
WO2012031031A2 (en) 2010-08-31 2012-03-08 Lawrence Ganeshalingam Method and systems for processing polymeric sequence data and related information
WO2012122546A2 (en) * 2011-03-09 2012-09-13 Lawrence Ganeshalingam Biological data networks and methods therefor
WO2013192631A1 (en) 2012-06-22 2013-12-27 Maltbie Dan System and method for secure, high-speed transfer of very large files
ES2665543B1 (es) 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos
JP7436383B2 (ja) 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞
EP4103591A4 (de) 2020-02-13 2024-09-04 The Board of Trustees of the Leland Stanford Junior University T-zellen und hämatopoetische stammzellenvorläufer zur behandlung von patienten mit ipex-syndrom basierend auf dem foxp3-gen (crispr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
JP2001519666A (ja) * 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
GB9721909D0 (en) 1997-10-17 1997-12-17 Cantab Pharma Res Gene delivery vectors and their uses
AU756827B2 (en) 1997-10-21 2003-01-23 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors
WO1999020779A1 (en) 1997-10-21 1999-04-29 Targeted Genetics Corporation Amplifiable adeno-associated virus (aav) packaging cassettes for the production of recombinant aav vectors
EP1105479B1 (de) * 1998-08-11 2011-01-12 Darwin Discovery Limited Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
EP1967525B1 (de) * 2001-05-08 2012-11-14 Darwin Molecular Corporation Verfahren zur Regulierung der Immunfunktion in Primaten unter Verwendung des foxp3-Proteins

Also Published As

Publication number Publication date
CA2339409A1 (en) 2000-02-24
JP2012191949A (ja) 2012-10-11
US6683160B1 (en) 2004-01-27
US6667162B1 (en) 2003-12-23
AU5559499A (en) 2000-03-06
US20050164247A1 (en) 2005-07-28
US7135612B2 (en) 2006-11-14
US6884618B2 (en) 2005-04-26
JP2009039099A (ja) 2009-02-26
EP1105479B1 (de) 2011-01-12
US20080131411A1 (en) 2008-06-05
US20020168736A1 (en) 2002-11-14
DE69943129D1 (de) 2011-02-24
US7220579B2 (en) 2007-05-22
WO2000009693A3 (en) 2000-06-15
JP4351807B2 (ja) 2009-10-28
JP2010029204A (ja) 2010-02-12
US6683171B1 (en) 2004-01-27
US6794145B1 (en) 2004-09-21
US20050106601A1 (en) 2005-05-19
WO2000009693A2 (en) 2000-02-24
US6414129B1 (en) 2002-07-02
EP1105479A2 (de) 2001-06-13
JP2002538764A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
ATE495255T1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
NO20101157L (no) FAD4, FAD5, FAD5-2 og FAD6, nye fettsyredesaturase familiemedlemmer og anvendelser derav
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
BRPI0411182A (pt) método para aumentar a toleráncia de uma planta ao estresse abiótico, método para aumentar a biomassa de uma planta, construto de ácido nucléico, polipeptìdio isolado e célula de planta
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
DE69829857D1 (de) Hypoxie-regulierte gene
ATE215988T1 (de) Vitamin-k-abhängige carboxylase
EP1509251A4 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
EP1546375A4 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
WO1999027098A3 (en) A-33 related antigens and their pharmacological uses
DK1364023T3 (da) Gener, de udtrykkes i höje niveauer i bruskvæv
DK0724637T3 (da) Kortikotropinfrigørende faktor2-receptorer
NZ307444A (en) Polyphenol oxidase genes from lettuce and banana
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
ATE161049T1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
DK0904356T3 (da) Aspergillus Oryzae 5-aminolevulinsyre-synthaser og nukleinsyrer, der koder disse
NO20025146L (no) Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav
BR0014926A (pt) Sistema de produção de proteìna
DE69632963D1 (de) Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung
DE69738433D1 (de) Rezeptor-tyrosine-kinase gene
EP1475388A3 (de) Neue Untereinheiten eines kalzium-sensitiven Kaliumkanals
DK0778347T3 (da) Protein med formodede helicase- og ATPase-egenskaber, som binder ATP og nukleinsyre
MX9707259A (es) Homologos de celubrevinas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties